Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy.
On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver
The trial results show that VERVE-102 successfully reduced PCSK9 by up to 88% and LDL-C by up to 62%. The investigational drug was well tolerated across all dose levels, with no related adverse events or dose-limiting toxicities. The top-line results indicate that the candidate drug could offer a novel approach for achieving substantial and durable LDL-C reduction with a one-time treatment.
Eli Lilly senior vice president and co-founder of Verve Therapeutics, Sekar Kathiresan, insists the trial results affirm that a single dose of VERVE-102 may mimic the LDL-C-lowering effects of PCSK9 cardioprotective variants. Consequently, it could transform cardiovascular care from chronic management to one-time treatment. The US Food and Drug Administration has already granted Fast Track designation for VERVE-102 for the reduction of LDL-C in participants with hyperlipidemia and high lifetime cardiovascular risk.